EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

“If your itching is caused by a liver problem, there won’t be a skin rash or an insect bite,” the Liver Foundation says. The ...

Lisa Woodcock's initial instinct when she first developed severe itching all over her body was to blame an allergic reaction to her laundry detergent. 'I was itching all the time,' recalls the 41-year ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Key Efficacy Outcomes: Pruritus and Sleep Interference Over a 24-week period, patients receiving linerixibat experienced a statistically significant reduction in worst itch scores compared to placebo, ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients with primary biliary cholangitis (PBC), the randomized phase III ...

Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure.